scholarly journals Role of Dissolved Oxygen during the Inhibition of the Corrosion of Iron by Sodium Phosphate Solutions

Nature ◽  
1951 ◽  
Vol 167 (4239) ◽  
pp. 157-157 ◽  
Author(s):  
M. J. PRYOR ◽  
M. COHEN
2016 ◽  
Vol 68 (6) ◽  
pp. 595-603 ◽  
Author(s):  
G. Genchev ◽  
C. Bosch ◽  
E. Wanzenberg ◽  
A. Erbe

Author(s):  
Yingming Guo ◽  
Ben Ma ◽  
Jianxiong Huang ◽  
Jing Yang ◽  
Ruifeng Zhang

Abstract The iron and manganese oxide filter film (MeOx) were used to research the simultaneous removal of bisphenol A (BPA), manganese (Mn2+) and ammonium (NH4+) in a pilot-scale filter system. We found that 0.52 mg/L of BPA could be removed while consuming 5.44 mg/L of dissolved oxygen (DO). Since the oxidation process of NH4+ and BPA both consume the DO in water, the presence of NH4+ can hinder the removal of BPA. The presence of Mn2+ in water had a synergy effect on the BPA removal. The filter film was characterized by SEM, XRD and XPS. Some substances were generated to block the pores of the oxide film, and a small amount of film was found to crack and fall off. The elemental composition of C and O were both increased by about 9%, the composition of Mn was decreased from 63.48% to 44.55%, and the reduced manganese substance might affect the activity of the oxide film. The main chemical forms of MeOx are Mn6O12·3H2O, MnFe2O4 or Mn3O4. The decrease in the removal efficiency of BPA was mainly due to the C-containing intermediate [−CH2C − H(OH)]n covering the surface of the oxide film and blocking the pore size of the film.


2019 ◽  
Vol 161 ◽  
pp. 79-88 ◽  
Author(s):  
Huanyu Lei ◽  
Jiaming Lu ◽  
Guoqing Dong ◽  
Guofeng Tian ◽  
Shengli Qi ◽  
...  

2017 ◽  
Vol 70 (1) ◽  
Author(s):  
William Perks ◽  
John Iazzetta ◽  
Pak Cheung Chan ◽  
Athina Brouzas ◽  
Shirley Law ◽  
...  

<p><strong>ABSTRACT</strong></p><p><strong>Background:</strong> Sodium phosphate injection is used to treat moderate to severe hypophosphatemia. There have been no published reports documenting the physical compatibility or chemical stability of sodium phosphate injection in IV solutions.</p><p><strong>Objective:</strong> To evaluate the physical compatibility and chemical stability of 30 and 150 mmol/L solutions of phosphate, prepared from sodium phosphate injection, in 5% dextrose in water (D5W) and in 0.9% sodium chloride (normal saline [NS]) and stored in polyvinyl chloride (PVC) bags at 23°C or 4°C over 63 days.</p><p><strong>Methods:</strong> On study day 0, solutions of phosphate 30 and 150 mmol/L in D5W or NS were prepared in PVC bags and stored at 4°C and 23°C. On prespecified days during the 63-day study period, the concentrations of sodium and phosphate were determined, and admixture weight was checked to assess moisture loss during storage without a plastic overwrap. Chemical stability was calculated from the intersection of the lower 95% confidence limit of the degradation rate and the lower limit of acceptability (90%) for concentration remaining.</p><p><strong>Results:</strong> The analytical methods for both sodium and phosphate were found to be precise (coefficient of variation averaging less than 1% for pre-study validation samples). Both sodium and phosphate retained more than 94% of the initial concentration over the 63-day study period. With 95% confidence, the time to achieve 90% of the initial concentration of both sodium and phosphate approached or exceeded the 63-day study period, regardless of temperature, concentration, or base solution.</p><p><strong>Conclusions:</strong> Sodium phosphate solutions at a phosphate concentration of 30 or 150 mmol/L in either NS or D5W retained more than 94% of the initial concentration of both sodium and phosphate over 63 days when stored at 23°C or 4°C. In compliance with United States Pharmacopeia General Chapter &lt;797&gt; recommendations, a beyond-use date of 14 days (with refrigeration) or 48 h (room temperature) may be applied. Extending the beyond-use date beyond these limits may be considered, if a validated sterility test is performed.</p><p><strong>RÉSUMÉ</strong></p><p><strong>Contexte :</strong> Le phosphate de sodium injectable est employé pour traiter l’hypophosphatémie modérée et grave. À ce jour, aucun rapport portant sur la compatibilité physique ou la stabilité chimique du phosphate de sodium injectable contenu dans les solutions intraveineuses n’a été publié.<strong> </strong></p><p><strong>Objectif :</strong> Évaluer la compatibilité physique et la stabilité chimique de solutions de phosphate à des concentrations de 30 et de 150 mmol/L préparées à partir de phosphate de sodium injectable dilué dans du dextrose à 5 % dans l’eau (D5E) ou du chlorure de sodium à 0,9 % (solution physiologique salée [SP]) puis rangées dans des sacs de polychlorure de vinyle (PVC) à des températures de 4 °C ou de 23 °C pendant 63 jours.</p><p><strong>Méthodes :</strong> Au jour 0 de l’étude, les solutions de phosphate à des concentrations de 30 et de 150 mmol/L ont été préparées avec du D5E ou de la SP dans des sacs de PVC, puis entreposées à des températures de 4 °C ou de 23 °C. À des jours donnés pendant la période de 63 jours de l’étude, on a évalué les concentrations de sodium et de phosphate et l’on a pesé les mélanges pour vérifier la perte d’humidité pendant un entreposage n’utilisant pas de suremballage de plastique. La stabilité chimique était calculée au point d’intersection entre la limite inférieure de confiance à 95 % du taux de dégradation et la limite inférieure d’acceptabilité (90 %) de la concentration restante.</p><p><strong>Résultats :</strong> Les méthodes analytiques employées pour évaluer le sodium et le phosphate se sont révélées précises (coefficient de variation moyen inférieur à 1 % pour les échantillons aux fins de validation avant l’étude). Le sodium et le phosphate conservaient chacun plus de 94 % de leurs concentrations initiales pendant la période d’étude de 63 jours. Avec un niveau de confiance de 95 %, le temps nécessaire pour atteindre 90 % de la concentration initiale pour le sodium et pour le phosphate approchait ou dépassait les 63 jours de la période d’étude, peu importe la température, la concentration ou la solution de base.</p><p><strong>Conclusions :</strong> Les solutions de phosphate de sodium dont la concentration en phosphate est de 30 ou de 150 mmol/L, qu’elles soient à base de D5E ou de SP, conservaient plus de 94 % des concentrations initiales de sodium et de phosphate pendant 63 jours, qu’elles soient entreposées à des températures de 4 °C ou de 23 °C. Conformément aux recommandations contenues dans le chapitre &lt;797&gt; de la United States Pharmacopeia, une date limite d’utilisation de 14 jours (sous réfrigération) ou de 48 heures (à température ambiante) peut être utilisée. Allonger la date limite d’utilisation au-delà des bornes fixées par l’organisme américain peut être envisageable si une épreuve validée de stérilité est réalisée.</p>


1983 ◽  
Vol 23 ◽  
Author(s):  
John C. C. Fan ◽  
B-Y. Tsaur ◽  
C. K. Chen ◽  
J. R. Dick ◽  
L. L. Kazmerski

ABSTRACTUsing secondary-ion mass spectroscopy, we have found that oxygen is strongly concentrated at the sub-boundaries in zone-melting-recrystallized silicon-on-insulator films prepared by the graphite-strip-heater technique. This observation suggests that the formation of sub-boundaries during recrystallization may be caused by constitutional supercooling resulting from the presence of oxygen that is dissolved into the molten Si zone from the adjacent SiO2 layers. Since all zone-melting-recrystallized films to date have been bordered by SiO2 layers, regardless of the heating techniques employed, the sub-boundaries almost always present in these films may well have dissolved oxygen as their common origin.


Chemosphere ◽  
2018 ◽  
Vol 194 ◽  
pp. 675-681 ◽  
Author(s):  
Sin-Li Lee ◽  
Li-Ngee Ho ◽  
Soon-An Ong ◽  
Yee-Shian Wong ◽  
Chun-Hong Voon ◽  
...  

1986 ◽  
Vol 21 (4) ◽  
pp. 221-224 ◽  
Author(s):  
J. E. O. Mayne ◽  
J. A. Burkill

Sign in / Sign up

Export Citation Format

Share Document